Adrenergic receptors: The key therapeutic target

Journal of Clinical and Basic Cardiology

Volumn 7, Issue 1-4, 2004, Pages 30-32

  Gregorini, Luisa ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NITRATE; NITROPRUSSIDE SODIUM; PAPAVERINE; PHENTOLAMINE; URAPIDIL; VERAPAMIL;

CORONARY ARTERY CONSTRICTION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; LETTER; PRIORITY JOURNAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 14244251398     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (57)

1. Ahlquist RP. Study of adrenotropic responses. Am J Physiol 1948; 153: 586-600.
2. Hollenberg MD. Structure-activity relationships for transmembrane signaling: the receptor's turn. FASEB J; 5: 178-86.
3. Shan K, Bick RJ, Poindexter BJ et al. Altered adrenergic receptor density in myocardial hibernation in humans: A possible mechanism of depresed myocardial function. Circulation 2000; 102: 2599-606.
4. Heusch G. α-adrenergic mechanisms in myocardial ischemia. Circulation 1990; 83:1-13.
5. Motulsky HJ. Insel PA, Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations. N Engl J Med 1982; 307: 18-29.
6. Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor regulation: biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 1984; 310: 1570-9.
7. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Gates AE, Feldman AM. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82 (Suppl 1): 12-25.
8. Ruffolo RR Jr, Nichols AJ, Stadel JM, Hieble JR Structure and function of alpha-adrenoceptors. Pharmacol Rev 1991; 43: 475-505.
9. Caron MG, Lefkowitz RJ. Catecholamine receptors: structure, function, and regulation. Recent Prog Horm Res 1993; 48: 277-90.
10. 1-adrenergic receptors in the failing human heart. Circulation 1993; 87: 454-63.
11. 2-adrenergic receptor. Science 1994; 264: 582-6.
12. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic Polymorphisms of β1- and 2C-Adrenergic Receptors and the Risk of Congestive Heart Failure. New Engl J Med 2002; 347: 1135-42.
13. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002; 415: 206-12.
14. Woodman OL, Vatner SF: Coronary vasoconstriction mediated by α1- and α2-adrenoceptor in conscious dogs. Am J Physiol 1987; 253: H388-93.
15. Jones CJM, DeFily DV, Patterson J, Chilian WM. Endothelium dependent relaxation competes with α1- and α2-adrenergic constriction in the coronary microcirculation. Circulation 1993; 87: 1264-74.
16. Fischell TA, Derby G, Tse TM, Stadius ML. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty: A quantitative arteriographic analysis. Circulation 1988; 78: 1323-34.
17. Hanet C, Wijns W, Michel X, Schroeder E. Influence of balloon size and stenosis morphology on immediate and delayed elastic recoil after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1991; 18: 506-11.
18. Golino P, Ashton JH, Buja LM, Rosolowski M, Taylor AL, McNatt J, Campbell WB, Willerson JT. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries invivo. Thromboxane A2 and serotonin are possible mediators. Circulation 1989; 79: 154-66.
19. El Tamimi H, Davies GJ, Maseri A, Hackett D, Sritara P, Bertrand O, Crea F, Maseri A. Abnormal vasomotor changes early after coronary angioplasty. A quantitative arteriographic study of their time course. Circulation 1991; 84: 1198-202.
20. Gregorini L, Fajadet J, Robert G, Cassagnean B, Bernis M, Marco J. Coronary vasoconstriction following percutaneous transluminal coronary angioplasty is attenuated by anti-adrenergic agents. Circulation 1994; 90: 895-907.
21. Malliani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol 1969; 217: 703-9.
22. Indolfi C, Piscione F, Ceravolo R, Maione A, Focaccio A, Rao MA, Esposito G, Condorelli M, Chiariello M. Limb vasoconstriction after successful angioplasty of the left anterior descending coronary artery. Circulation 1995; 92: 2109-12.
23. Heyndrickx GR, Millard RW, McRitchie RJ. Maroko PR, Vatner SF. Regional myocardial function and electrophysiological alterations after brief coronary occlusion in conscious dogs. J Clin Invest 1975; 56: 978-85.
24. Vatner S. Correlation between acute reductions in myocardial blood flow and function in conscious dogs. Circ Res 1980; 47: 202-7.
25. Gregorini L, Marco J, Patombo C, Kozàkovà M, Anguissola GB, Cassagneau B, Bernies M, Distante A, Fajadet J. Zanchetti A. Post-ischemic LV dysfunction is abolished by alpha-adrenergic blockers. J Am Coll Cardiol 1998; 31: 992-1001.
26. Gregorini L, Marco J, Kozàkovà M, Palombo C, Anguissola GB, Cassagneau B, Bernies M, Distante A, Marco I, Fajadet J, Hensch G. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 99: 482-90.
27. Gillis RA, Dretchen KL, Namath I, Anastasi N, Dias Souza J, Hill K, Browne RK, Quest JA. Hypotensive effect of urapidil: CNS site and relative contribution. J Cardiovasc Pharmacol 1987; 9: 103-8.
28. Kolassa N, Beller KD, Sanders KH. Involvement of brain 5HT1A receptor in the hypotensive response to urapidil. Am J Cardiol 1989; 64: 7D-20D.
29. Braunwald E, Kloner RA The stunned myocardium: Prolonged postischemic ventricular dysfunction. Circulation 1982; 66: 1146-9.
30. Vatner SF, Hintze TH. Mechanism of constriction of large coronary arteries by β-adrenergic receptor blockade. Circ Res 1983; 53: 389-400.
31. 2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation 2002; 106: 2901-7.
32. Kern MJ, Deligonul U, Vandormael M, Labovitz A, Gudipati CV, Gabliani G, Bodet J, Shah Y, Kennedy HL. Impaired coronary vasodilator reserve in the immediate post coronary angioplasty period: analysis of coronary artery flow velocity indexes and regional cardiac venons efflux. J Am Coll Cardiol 1989; 13: 860-72.
33. Uren NG, Crake T, Lefroy D, de Silva R, Davies GJ, Maseri A. Delayed recovery of coronary resistive vessel function after coronary angioplasty. J Am Coll Cardiol 1993; 21: 612-21.
34. van Liebergen RAM, Pick JJ, Kock KT, Lie KI. Immediate and long-term effect of balloon angioplasty or stent implantation on the absolute and relative coronary flow velocity reserve. Circulation 1998, 98: 2133-40.
35. Wilson RF, Lesser JR, Laxon DD, White SW Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; 1: 807-11.
36. Hori M, Inoue M, Kitakaze M, Koretsune Y, Iwai K, Tamai J, Ito H, Kitabatake A, Sato T, Kamada T. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol 1986; 250: H509-18.
37. Hori M, Tamai J, Kitakaze MT, Iwakura K, Gotoh K, Iwai K, Koretsune Y, Kagiya T, Kitabatake A, Kamada T. Adenosine-induced hyperemia attenuates myocardial ischemia in coronary microembolization in dogs. Am J Physiol 1989; 257: H244-51.
38. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105: 1285-90.
39. 1-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol 1985; 5: 840-6.
40. Furberg CD on behalf of the ALLHAT investigators. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2000; 283: 1967-75.
41. Sica DA. ALLHAT: Is the Final Answer in? Heart Dis 2003; 5: 171-5.
42. 1-Adrenoceptor activity regulates release of adenosine from ischemic myocardium in the dogs. Circ Res 1987; 60: 633-9.
43. Nishigaki K, Faber JE, Ohyanagi M. Interaction between α-adrenoceptors and adenosine receptors on microvascular smooth muscle. Am J Physiol 1991; 29: H1655-H1666.
44. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995; 92: 2135-41.
45. Zanzinger J, Czachurski J, Seller H. inhibition of sympathetic vasoconstriction is a major principle of vasodilatation by nitric oxide in vivo. Circ Res 1994; 75: 1073-7.
46. Kozàkovà M, Marco J, Heusch G, Bernies M, Bossi IM, Palombo C, Anguissola GB, Donatelli F, Laurent JP, Gregorini L. The α-1 adrenergic blocker urapidil improves contractile function in patients three months after coronary stenting: a randomized double-blind study. Am Heart J 2004; 147: E6.
47. Wilson RF, Lesser JR, Laxon DD, White SW Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; 1: 807-811.
48. Reffelmann T, Hale SL. Dow JS, Kloner RA. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation 2003; 108: 2911-7.
49. Felled H, Lichstein E, Schachter J, Shani J. Early and late angiographic findings of the 'no-reflow' phenomenon following direct angioplasty as primary treatment of anterior myocardial infarction. Am Heart J 1992; 123; 782-5.
50. Piana RN, Paik GY, Mescucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Baim DS. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-8.
51. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CD, Popma JJ, Piana R. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-6.
52. Sdringola S, Assali A, Ghani M, Yepes A, Rosales O, Schroth GW, Fujise K, Anderson HV, Smalling RW Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv 2000; 51: 394-9.
53. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132: 959-63.
54. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996; 39: 113-8.
55. Gregorini L, Marco J, Bernies M, Cassagneau B, Pomidossi G, Anguissola GB, Fajadet J. The α1-adrenergic blocking agent urapidil counteracts post-rotational atherectomy "clastic recoil" where nitrates have failed. Am J Cardiol 1997; 79 1100-3.
56. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37: 1335-43.
57. Ochs JG, Storck J, Kirsten R. Urapidil inhibits serotonin induced aggregation of thrombocytes in hypertonics. Klin Wochenschr 1990; 69 (Suppl XIX): 47.